News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Euro News, Articles and Videos with Contenting
1. "EU Proposes New Rules on Digital Tax to Make Tech Giants Pay Their Share" - This article from Reuters discusses how the European Union's executive branch proposed new rules for digital taxation to ensure tech giants pay their fair share of taxes. The new rules are set to impact companies like Amazon, Apple, Facebook, and Google. 2. "Germany, France and Italy Sign Pact to Tax Digital Giants" - This article from the New York Times discusses how Germany, France, and Italy have signed a pact to tax digital companies such as Amazon, Apple, Facebook, and Google. The agreement is the first major step in the European Union's effort to tax tech giants. 3. "EU's New Digital Tax Plan: What You Need to Know" - This video from Euronews explains the European Union's new digital tax plan and how it will affect tech giants such as Amazon, Apple, Facebook, and Google. The video also explains the different aspects of the plan and how it will be implemented.
THEON accelerates strategic expansion in the Baltic Region - ForexTV
THEON representatives with Latvian Ministry of Economy at Baltic Optronics THEON representatives with Latvian Ministry of Economy at Baltic Optronics PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS) 4 July 2025 – Theon International Plc (THEON), a leading global manufacturer of night vision and thermal imaging systems, today announces a significant acceleration of its strategic footprint in the Baltic defense market through a renewed collaboration in Estonia and a pivotal investment in Latvia. These moves underscore THEON's commitment to enhancing European defense resilience and strategic autonomy. Firstly, THEON proudly announces the continuation of its collaboration with the Estonian Center for Defense Investment (ECDI) of the Ministry of Defense. THEON and ECDI signed a new agreement for supplying advanced night vision systems to the Estonian Defense Forces (part of orders that have already been announced), reinforcing a vital partnership in the region. Secondly, in a landmark move to bolster its European production capabilities and presence in the region (in alignment with mid-term Capex guidance), THEON launched a strategic investment in “Baltic Photonics”, the Riga-located Latvian subsidiary of "Harder Digital". This investment marks the first phase in establishing a state-of-the-art manufacturing facility focused on the production of critical Image Intensifier Tube (IIT) components, starting with MCP (Multi Channel Plate). The facility will also provide essential assembly and maintenance services for THEON’s end-products destined for the Baltic states. The new facility, which has been supported by the Latvian Ministries of Economy and Defense, will concentrate on: manufacturing critical components, strengthening the supply chain for European IIT producerslocalizing assembly of THEON’s advanced electro-optical end-products to optimize responsiveness to Baltic states’ market demandsexpanding production capabilities to include new opto-electronic products for the broader European market. Gabriel Robolis, THEON’s Regional Director of Business Development, commented: “This dual milestone in Estonia and Latvia is a testament to THEON's unwavering commitment to strengthening Europe's defense industrial base. By expanding our production capacity and deepening our regional footprint, we are reducing time-to-market and equipping Europe with cutting-edge technology, contributing to the continent's defense resilience and autonomy.” Picture: THEON representatives with Latvian Ministry of Economy at Baltic Optronics For inquiries, please contact: Investor RelationsNikos MalesiotisE-Mail: ir@theon.comTel: +30 210 6772290Media ContactElli MichouE-Mail: press@theon.com Tel: +30 210 6728610 About THEON GROUPTHEON GROUP of companies develops and manufactures cutting-edge night vision and thermal Imaging systems for Defense and Security applications with a global footprint. THEON GROUP started its operations in 1997 from Greece and today occupies a leading role in the sector thanks to its international presence through subsidiaries and production facilities in Greece, Cyprus, Germany, the Baltics, the United States, the Gulf States, Switzerland, Denmark, Belgium, Singapore and South Korea. THEON GROUP has more than 200,000 systems in service with Armed and Special Forces in 71 countries around the world, 26 of which are NATO countries. ΤΗΕΟΝ ΙΝΤΕRNATIONAL PLC has been listed on Euronext Amsterdam (AMS: THEON) since February 2024.www.theon.com Attachments Press Release_Baltics 04.07.2025 2 THEON representatives with Latvian Ministry of Economy at Baltic Optronics
Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner - ForexTV
The expert jury selected Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D. of Araris Biotech, from a group of outstanding life science entrepreneursThe founding team is developing a breakthrough technology to establish a new generation of targeted cancer therapiesCommittee representatives presented the award and the EUR 100,000 cash prize on Thursday, July 3, 2025 Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year’s winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech’s founding team distinguished itself not only by developing of a novel technology in the antibody-drug conjugates (ADCs) field, but also by successfully validating this innovation through partnerships and a preclinical exit. This new drug class has the potential to significantly advance the development of targeted cancer therapies, thereby delivering added value for people living with cancer worldwide. “On behalf of the award committee and this year’s expert jury panel, we would like to congratulate Isabella Attinger-Toller, Dragan Grabulovski and Philipp Spycher. Together with the expert jury, we selected the founders of Araris Biotech as winners based on their combined leadership, entrepreneurial expertise and scientific excellence. Following the successful acquisition of Araris by Taiho Pharmaceuticals, we believe this award further recognizes the founding team’s continued growth and positive trajectory ahead. This trio has impressively demonstrated how a new idea, a clear focus on translation and entrepreneurial boldness can come together to launch a new generation of targeted cancer therapies,” said Andreas Strüngmann, M.D., and Thomas Strüngmann, Ph.D., in a joint statement. “It was a special privilege for us to engage with such a diverse, forward-looking group of start-ups from the DACH region. Learning more about the finalists and their impressive achievements made the final decision anything but easy.” The group of finalists selected in May comprised three companies: Araris Biotech, NovaGo Therapeutics and TOLREMO therapeutics, whose founders exemplify the entrepreneurial potential and scientific diversity that characterize the life sciences sector in the DACH region. They include an impressive variety of disciplines — spanning targeted cancer therapies, regenerative neuroscience and cancer drug resistance. Following the presentation of their entrepreneurial and scientific achievements to an expert jury, Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., were announced today as the winning team and will receive a joint cash prize of EUR 100,000. "We feel very honored to have our vision and achievements recognized by the Strüngmann Award. As the founding team, we have always believed in the potential of our new technology and the value it may hold for patients. This award, in addition to the acquisition by Taiho Pharmaceuticals, is a validation of our commitment, shared journey and the hard work that has enabled our success story," said Dragan Grabulovski, Ph.D., CEO of Araris Biotech, on behalf of the founding team. The Araris Biotech founders, the experienced biotech entrepreneur Dragan Grabulovski, Ph.D., (CEO), the visionary scientist Philipp Spycher, Ph.D., (CSO) and the outstanding translational scientist Isabella Attinger-Toller, Ph.D., (CTO), can look back on one of the most successful Swiss biotech startups to be established in recent years. Spun out of the Paul Scherrer Institute (part of ETH domain) in 2019, the team developed a novel ADC linker-payload technology (AraLinQ™) that enables one-step payload attachment to off-the-shelf antibodies, without the need for prior antibody engineering. This innovative approach not only opens new possibilities in oncology, but also has potential for applications in other therapeutic areas. In only a few years, the Araris team raised over CHF 40 million, formed a strategic partnership with Chugai (Roche) and Johnson & Johnson, and achieved a landmark acquisition by Taiho Pharmaceutical in March 2025 for up to USD $1.14 billion. Through these achievements, the three winners exemplify the potential within the DACH region to successfully translate scientific excellence into global innovation. About the Strüngmann AwardThe award was established in 2024 to recognize outstanding entrepreneurs realizing revolutionary ideas in the DACH life science sector. The goal is to reward exceptional achievements with a prestigious prize and to further the development of the next generation of leaders in this space. The award was named to honor twin brothers Andreas Strüngmann, M.D., and Thomas Strüngmann, Ph.D., who are among the important entrepreneurs, visionaries and investors in the life science sector. As the founders of Hexal, they achieved extraordinary entrepreneurial success and as investors, they have continued to repeat that success for more than 20 years by building and developing leading companies across the industry, including Mainz-based BioNTech. Learn more at https://struengmannaward.de/. About Araris Biotech AGAraris Biotech is a leading biotech company pioneering the future of antibody-drug conjugates (ADCs) and redefining the entire paradigm of targeted cancer therapy and beyond. Araris’ vision is a world without chemotherapy and its proprietary conjugation and groundbreaking multi-payload technology represents a quantum leap forward in ADC design, enabling the transformation of any antibody into an ADC with the goal of better safety and efficacy. By enabling the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, Araris is creating a new generation of smart missiles that deliver the potency of combination chemotherapy in a targeted fashion in order to tackle the persistent challenges of cancer resistance. Araris is a wholly owned subsidiary of Taiho Pharmaceutical following its acquisition in March 2025. For more information about our science and pipeline, please visit https://www.ararisbiotech.com/. Media ContactTrophic CommunicationsStephanie May, Ph.D. and Anja HeuerPhone: +49 (0) 171 185 56 82Email: athos@trophic.eu Attachment Strüngmann Award 2025 Goes To Araris Biotech
Alyona Dehrik-Shevtsova: From Kyiv Roots to Global Fintech and Social Impact - TechBullion
For Alyona Dehrik-Shevtsova, ambition has never been confined by borders. Born on December 17, 1987, in Ukraine, Alyona has spent the past two decades transforming her academic foundation, sharp business instincts, and deep sense of social responsibility into an international career that now extends far beyond her home country. While her impact today spans Europe, […]
UK AI Venture Capital boom drives record investment in H1 2025 - Dealroom - UK Investor Magazine
The United Kingdom has cemented its position as Europe’s undisputed leader in VC funding in the first half of 2025, with AI startups raising a record $2.4 billion in the first half of 2025 – accounting for 30% of all UK venture capital funding, according to a new report from HSBC Innovation Banking and Dealroom. […]